Showing results (31-40 of 73) with videos related to

Sort By:
Pageof 8
Critical Reviews in Biomedical Engineering|August 3, 2016
Establishing Early Functional Perfusion and Structure in Tissue Engineered Cardiac ConstructsBo Wang, Sourav S Patnaik, Bryn Brazile, et al.
Proceedings of the National Academy of Sciences of the United States of America|October 1, 2016
Dysregulation of Notch and ERα signaling in AhR-/- male miceBo Huang, Ryan Butler, Yifei Miao, et al.
Frontiers in Veterinary Science|February 15, 2019
Laser Therapy for Incision Healing in 9 DogsJennifer L Wardlaw, Krista M Gazzola, Amanda Wagoner, et al.
Journal of Pediatric Surgery|September 3, 2025
Same Day Discharge Following Minimally Invasive Repair of Pectus ExcavatumCory Nonnemacher, Seth Saylors, Meredith Elman, et al.
Pain|January 1, 2008
Alvimopan, a peripherally acting mu-opioid receptor (PAM-OR) antagonist for the treatment of opioid-induced bowel dysfunction: results from a randomized, double-blind, placebo-controlled, dose-finding study in subjects taking opioids for chronic non-cancer painLynn Webster, Jan Peter Jansen, John Peppin, et al.
Journal of Personalized Medicine|May 27, 2023
Ligand-Gated Ion Channels: Prognostic and Therapeutic Implications for GliomasGrace Hey, Rohan Rao, Ashley Carter, et al.
The Journal of Pain|February 5, 2011
A randomized, placebo-controlled phase 3 trial (Study SB-767905/012) of alvimopan for opioid-induced bowel dysfunction in patients with non-cancer painJan-Peter Jansen, Daniel Lorch, John Langan, et al.
Journal of the American Academy of Audiology|October 4, 2018
Using Microphone Technology to Improve Speech Perception in Noise in Children with Cochlear ImplantsPatti M Johnstone, Kristen E T Mills, Elizabeth Humphrey, et al.
The Patient|June 28, 2021
Patient-Reported Outcomes in the Phase III BRIGHTE Trial of the HIV-1 Attachment Inhibitor Prodrug Fostemsavir in Heavily Treatment-Experienced IndividualsSarah-Jane Anderson, Miranda Murray, David Cella, et al.
Cells|January 8, 2023
Sleep-Disturbance-Induced Microglial Activation Involves CRH-Mediated Galectin 3 and Autophagy DysregulationLiyang Guo, Kirstin M Reed, Ashley Carter, et al.
Pageof 8